Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Potential Opportunities In Cosmetic Healthcare Highlighted Through SBC Medical’s Story

Benzinga

By Gerelyn Terzo, Benzinga Cosmetic healthcare is no longer reserved for Hollywood elites. Rising demand has increased access to aesthetic surgery, as technological advancements have paved the way for innovative financing options and less invasive procedures – placing it within the grasp of a wider swath of the population. Meanwhile, the market opportunity is growing and expected to increase, placing the advantage in the hands of companies that have already gained the trust of their consumers – brands like Japan’s SBC Medical Group Holdings (NASDAQ: SBC). According to Research and Markets, the global market for cosmetic surgery will grow by double digits in 2024 to reach a size of $53 billion. Furthermore, it will continue to grow at a compound annual growth rate (CAGR) of 8.4% over 2024-2028 to culminate in a market size of $73.22 billion. In a recent report, McKinsey & Company predicted that the medical aesthetics sector, particularly in the United States and Canada, is here for the long haul and has demonstrated strong resilience in the face of changing economic cycles. The North American market growth is being fueled by demand for injectable procedures like Botox. According to the report, consumers continue to spend on cosmetic procedures, a heightened focus on cost-effective products and treatments notwithstanding. Demand is two-pronged, comprising a growing segment of the population who are most interested in the cosmetic benefits of self-care as well as those facing medical issues such as skin conditions in search of relief. Either way, the cosmetic healthcare industry seems poised for growth, and companies like SBC Medical Group are working hard to position themselves to continue to benefit from these macro trends. As a provider of comprehensive consulting and management services to medical corporations and their clinics, SBC Medical boasts the largest network of franchised clinics in Japan and a leading position in the aesthetic medical industry. The company’s revenue is growing as the number of clinics under its umbrella continues to expand. SBC Medical Group: A Case Study In Expansion In Aesthetics SBC Medical Group enjoys a dominant industry position in its home market of Japan, where it estimates it enjoys a 31% share of the market across hundreds of clinics. However, the company’s management team remains ambitious and has set its sights on expansion as SBC continues to take ground in cities like Irvine, CA and Ho Chi Minh City, Vietnam. Most recently, the company announced it has entered into a definitive agreement to acquire Aesthetic Healthcare Holdings Pte. Ltd. ("AHH"), a privately-held Singapore-based company that owns and operates several brands that provide aesthetic medical treatments, in an all-cash transaction. The acquisition by SBC of AHH marks the first step in the company’s strategy to grow its business through acquisitions, which includes plans to expand its business internationally with a primary focus on the U.S. and Asia markets. The company believes Singapore represents the ideal hub for the further development of its brand in the region. Furthermore, while the cosmetic surgery market is growing around the world, SBC Medical has managed to exceed the average growth rate. The company reports that its five-year revenue CAGR between 2018 and 2023 hovered at 24%, far outpacing the industry’s growth rate. SBC Medical attributes its growth largely to clinics that, under its leadership, are expanding their sales and customer base in Japan and beyond. The company benefits from a diversified revenue model in which it collects sales through different types of services, including management, procurement, rental and royalty income. While the market opportunity may already seem attractive, there may still be a growth story yet to unfold in the cosmetic healthcare market. For example, aesthetic medicine penetration among women up to their 30s in age is still increasing, fueled largely by demand for medical needs involving dermatology treatments. With total market penetration hovering at a modest 10%, as per estimates compiled by SBC, there is still plenty of room for further growth as the industry finds ways to reach middle-aged female and male patients whose ages range from 40 to 60. Cosmetic surgery among men has been growing as many search for cures like hair loss treatments and laser hair removal. To capture a potential windfall, SBC Medical is developing dermatology-focused services under its SBC brand and expanding laser hair removal to dermatology clinics via its Rise Clinics. While competition may be growing as more companies look to jump on the bandwagon, SBC Medical Group reports that it enjoys key advantages, not least its early-mover industry position. To maintain its lead, SBC is hyper-focused on growth, including expansions into adjacent medical fields such as treatments for fertility and hair loss, while it also looks to strike key business-to-business partnerships through which it can leverage complementary strengths. With an income statement comprising double-digit revenue growth, gross profit margin and operating profit margin, SBC Medical Group’s approach may already be paying off. Interested investors who are looking to add exposure to this market opportunity to their portfolios can learn more about SBC Medical’s stock on the company’s website sbc-holdings.com/en Featured photo by Adeolu Eletu on Unsplash. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 27, 2024 12:00 PM Eastern Standard Time

Image

Copperleaf Capital, LLC Partners with AmeriLife’s Brookstone Capital Management

AmeriLife

Brookstone Capital Management (“Brookstone”), a leading SEC-Registered Investment Advisory (RIA) firm and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with Copperleaf Capital, LLC, a financial planning firm and RIA based in Raleigh, North Carolina. Per the agreement, terms of the deal were not disclosed. "We're excited to join forces with Copperleaf Capital," said Dean Zayed, CEO of Brookstone Capital Management. "This partnership strengthens our organization and allows us to continue delivering best-in-class solutions for our clients. By combining our expertise, we're expanding our holistic approach to wealth management and ensuring our clients benefit from a comprehensive range of insurance and securities services.” “This collaboration underscores Brookstone's ongoing commitment to supporting our advisors and leading the way in integrated financial solutions,” added Darryl Ronconi, president of Brookstone Capital Management. “Together, we're better positioned to help clients navigate the complexities of wealth management and achieve their long-term financial goals." With over 35 years of experience, Copperleaf Capital has invested in positively impacting families through strategic wealth management and financial planning. Copperleaf Capital’s proprietary, step-by-step discovery and planning process identifies specific areas where families and individuals can make sound financial decisions, turning dream retirement scenarios into actionable deployment to reach each client’s retirement goals. "I couldn’t be more excited to partner and expand our relationship with Brookstone," said Ryan Peterson, president of Copperleaf Capital. "They are the best partner to take us to the next level. The entire team is thrilled about the opportunity of aligning Copperleaf Capital with the extensive resources and talent that they offer." As an affiliate partner of AmeriLife’s Wealth Distribution platform, Copperleaf Capital will enjoy broad access to best-in-class platforms, tools, resources, and an expansive product portfolio to move quickly into new markets, accelerate production, and drive the firm’s growth for years. "Ryan and his team have created a formidable brand and business transforming retirement planning for Americans planning for or entering their retirement years," said Mike Vietri, Chief Distribution Officer for AmeriLife Wealth Group. "We're thrilled to have Copperleaf Capital join forces with Brookstone under the AmeriLife Wealth Group umbrella. Their distinctive approach, expertise, and leadership will be invaluable as we expand and strengthen our dynamic and holistic distribution platform." About Brookstone Capital Management Founded in 2006, Brookstone Capital Management (BCM) is an SEC-Registered Investment Advisory firm with over $10B in Assets Under Management (AUM). It provides fee-based investment management services through its network of more than 750 financial advisors and firms. Brookstone is an innovator and industry leader and empowers independent financial advisors of all sizes to scale their business by providing access to a Turnkey Asset Management Platform (TAMP) and a dedicated team to support every aspect of an advisor’s practice. Visit BrookstoneCM.com for more information. About Copperleaf Capital, LLC Copperleaf creates retirement strategies using various investment and insurance products designed to meet the needs and objectives of its clients. Copperleaf Capital, LLC, a registered investment advisor, provides investment advisory services. Insurance products are offered separately through Copperleaf’s representatives in their capacity as licensed insurance agents. For more information, visit CopperleafCapital.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents, financial professionals, and over 160 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. Contact Details Jeff Maldonado media@amerilife.com Partnership Inquiries Alex Hyer corporatedevelopment@amerilife.com Company Website https://amerilife.com/

November 25, 2024 09:00 AM Eastern Standard Time

Caregivers are the Heroes Among Us: Recognizing the Essential Role of Caregivers

YourUpdateTV

As our population ages, family health dynamics change, and healthcare complexities grow, the need for caregivers has never been greater. Yet, they often navigate their journeys in silence. In recognition of National Caregiver Month, Marvell Adams Jr., CEO of Caregiver Action Network, joined by caregiver Judy Krieg—who has cared for a loved one with Alzheimer’s disease— conducted a satellite media tour sponsored by Lundbeck and in conjunction with D S Simon Media. Together, Judy and Marvell shared insights on the caregiver journey and highlighted the " I Care " campaign, which celebrates the resilience and dedication of these remarkable individuals. A video accompanying this announcement is available at: https://youtu.be/pa5cw0kC55A In the U.S., more than half of those providing care don’t recognize themselves as caregivers. As a result, many do not access the tools that can alleviate caregiving stress. That’s why it’s important to help individuals identify themselves as caregivers and connect them with resources that can help make a difference. This year, during 2024 National Family Caregivers Month, Caregiver Action Network highlights the importance of self-recognition and self-identifying as a caregiver - key factors in caregivers’ access to essential support. Identifying as a caregiver opens the door to the family caregiver support needed throughout their journey. During this month, Caregiver Action Network also focuses on empowering caregivers and reminding them they are not alone in this journey. With the proper support and tools, one can continue to provide care while taking care of themselves. As Judy shares, she wishes she knew she wasn’t alone in the caregiver journey and had known more about symptoms of agitation associated with Alzheimer’s dementia. Resources to Share During 2024 National Family Caregivers Month There are many free resources available through the Caregiver Action Network to help those providing care navigate their caregiving journey: • Caregiver Help Desk – Access free, personalized support for your caregiving challenges. • 10 Tips for Family Caregivers – Learn practical strategies for managing caregiving stress. • Take Care of Your Mental Health – Use a free depression screener from the Caregiver Action Network to monitor your emotional well-being. • Connect with Other Family Caregivers – Join the Caregiver Action Network Community to share experiences and receive support. • Share Your Caregiver Story – Inspire others by sharing your caregiving journey. • Take Advantage of Resources from the I Care… Nonprofit Partners For more information, visit www.CaregiverAction.org ### BIO: Marvell Adams Marvell Adams Jr. is a highly skilled advocate, educator, and leader. He has a lifelong commitment to serving caregivers, marginalized communities, and older adults. After a nationwide search, the Board of Directors unanimously appointed Marvell as CEO of Caregiver Action Network. Marvell has shown dedication to serving caregivers since high school. He became fascinated with Alzheimer’s disease while completing a biology report. He pursued his education at the College of Charleston, earning a Bachelor of Arts in Political Science. Marvell later obtained a Master of Healthcare Administration specializing in Aging Services from the University of North Carolina – Chapel Hill. BIO: Judy Krieg Judy Krieg lives in Jackson, Michigan and assumed the role of caregiver for her parents when they began showing symptoms of Alzheimer’s disease (Mother) and Vascular Dementia (Father). Caring for two parents at once was physically and emotionally challenging. She became their Power of Attorney, attended medical appointments, moved them to assisted care and made them comfortable until they passed in 2020 and 2021. Judy’s mother displayed several agitation symptoms, including irritability, swearing, resisting help, and hoarding, and in addition she threatened suicide - making caregiving especially difficult. Despite an extensive career in pharmaceutical sales, focused on neuroscience, there was still a lot she didn’t know about being a caregiver. Judy is now a cheerleader and advocate for others who may be caring for a loved one and need support like she did. About CAN Caregiver Action Network (www.CaregiverAction.org) is the nation’s leading family caregiver organization working to improve the quality of life for more than 100 million Americans who care for loved ones with chronic conditions, disabilities, or diseases. CAN also supports those meeting the living needs of older adults. CAN serves a broad spectrum of family caregivers ranging from the parents of children with significant health needs. CAN (the National Family Caregivers Association) is a 501(c)(3) non-profit organization providing education, peer support, and resources to family caregivers across the country free of charge. About Lundbeck Lundbeck is a global biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, they are committed to improving the lives of people with neurological and psychiatric diseases. As a focused innovator, they strive for our research and development programs to tackle some of the most complex neurological challenges. For additional information on Lundbeck US, please visit Lundbeck.com/us. About D S Simon Media The firm is well known as a leader in the satellite media tour industry and produces tours from its studio and multiple control rooms at its New York headquarters. Clients include top brands in healthcare, technology, travel, financial services, consumer goods, entertainment, retail and non-profits. Established in 1986, the firm has won more than 100 industry awards. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 22, 2024 12:23 PM Eastern Standard Time

Video

Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study

Benzinga

By Meg Flippin, Benzinga Turning back the clock on aging is the holy grail for the longevity industry, but is something that has proven elusive. That may be changing, thanks to companies like Telomir Pharmaceuticals Inc. (NASDAQ: TELO). The pre-clinical-stage company positioning itself as an emerging leader in age-reversal science is making inroads with Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Results from a preclinical trial confirmed the efficacy of the compound, reports Telomir. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrated what Telomir said is significant age-reversal effects in aging model organisms treated with Telomir-1. These effects include an extended healthy lifespan, improved mobility and a measurable reversal of age-related decline. “The results we’re seeing with Telomir-1 mark an important step forward in our journey to potentially reverse aging in humans,” said Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals in a press release announcing the trial results. “This study confirms that Telomir-1 can reverse biological aging, extending life while preserving health. We are very excited about the potential applications of Telomir-1 as we progress toward human clinical trials” Anti-Aging In A Compound Telomir-1 is focused on telomere regeneration which involves repairing telomeres or the DNA structures that protect the ends of our chromosomes, similar to caps on shoelaces. Numerous studies have shown fixing them can extend a person’s biological age and even turn back the clock on certain diseases. Telomir Pharmaceuticals says Telomir-1 is a novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. The novel molecule, which Telomir is testing with mice and dogs with an eye toward human clinical trials, binds to critical metals that wear down telomeres. By limiting the availability of metals and interrupting the enzyme function, Telomir-1 seeks to restore cellular metal homeostasis and reverse a person's or animal’s biological age. The non-toxic oral therapy provides what the company says is a safe and effective alternative to existing treatments with minimal side effects. Telomir says Telomir-1 has the potential to impact patient care by offering new hope for managing and reversing age-related diseases and improving the quality of life for aging individuals. The Study Details The preclinical study, conducted in collaboration with Nagi Bioscience, utilized a sophisticated in vivo microfluidic-based assay to assess the effects of Telomir-1 on the nematode Caenorhabditis elegans, a well-established model for aging studies, reports Telomir. The microfluidic platform allowed precise, automated tracking of lifespan, healthspan and age-related mobility decline in real-time, enabling the research team to accurately measure the effects of Telomir-1 on these critical metrics. Two forms of Telomir-1 were administered in two concentrations. The study found that Telomir-1 significantly enhanced lifespan and healthspan parameters in aged microorganism populations. Some of the key findings include enhanced mobility in older organisms, reduced biological aging and increased lifespan. Subjects treated with Telomir-1 showed improved mobility, particularly in later stages of life compared to untreated controls. Telomir also said the study demonstrated “a measurable” reversal of biological age markers which the company said makes it a promising candidate for longevity treatments. What’s more, the company said Telomir-1 was associated with a statistically significant increase in lifespan among treated populations, further supporting Telomir-1’s role in promoting longevity. "At Nagi Bioscience, we are thrilled to contribute to this groundbreaking study through our innovative microfluidic technology, which allows precise and automated monitoring of aging and healthspan metrics in real-time,” said Dr. Laurent Mouchiroud, Chief Scientific Officer at Nagi Bioscience. “These results highlight Telomir-1’s remarkable potential to improve longevity and health, showcasing the power of cutting-edge tools in advancing age-reversal science." Expanding Telomir-1’s Reach Telomir sees many market opportunities for Telomir-1. There’s the longevity and anti-senescence therapy market, which is valued at $27.11 billion and is projected to reach $44.92 billion by 2031, growing at a CAGR of 6.8%. Then there’s Alzheimer's. Nearly seven million Americans suffer from this disease that attacks memory and cognitive functions. By 2050 that’s forecast to reach close to 13 million. And let's not forget cancer, another area Telomir-1 could prove effective in fighting. The global oncology market size is projected to reach $521.60 billion by 2033, growing at a CAGR of 8.9% from now until then. An additional area where Telomir-1 may help is in the treatment of progeria, a rare genetic disorder that causes accelerated aging in children. Telomir is intensifying its focus on the potential use of Telomir-1 to treat progeria and has engaged with the Progeria Foundation to investigate the effects of Telomir-1 on human progeria cell lines. This study will directly assess Telomir-1’s ability to counteract accelerated aging at the cellular level, offering critical insights into its therapeutic potential for progeria patients. Telomir also planned an in vivo study utilizing a progeria Caenorhabditis elegans model. This advanced microfluidic-based assay will evaluate Telomir-1’s impact on longevity, healthspan and biological aging in an organismal context. Telomir said these two studies represent a comprehensive approach to understanding Telomir-1’s effects on progeria, targeting both cellular and whole-organism models of the disease. On the canine front, Telomir is in talks with the North Carolina State College of Veterinary Medicine to establish a large-scale study on elderly dogs with osteoarthritis, further exploring Telomir-1’s potential to improve joint health and mobility. Turning back the clock on aging is the quest of many companies. Telomir believes it's getting closer to the successful formula. With the company all in with Telomir-1, stay tuned for more news on the trial front from this early-stage anti-aging innovator. Featured photo by JD Mason on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 22, 2024 09:00 AM Eastern Standard Time

Image

BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Benzinga

By Meg Flippin, Benzinga BioRestorative Therapies, Inc. (NASDAQ: BRTX), a regenerative medicine company focused on stem cell-based therapies and products, is advancing toward profitability, narrowing its loss in the third quarter and releasing favorable data for its BRTX-100 treatment for chronic back pain. The third quarter was a busy period for BioRestorative, as it secured a new patent, released what it says is encouraging trial data and continued licensing discussions with a commercial-stage regenerative medicine company – while also reducing its losses. For the three months ending Sept. 30, 2024, BioRestorative posted an operating loss of $2.3 million, marking a 26% year-over-year improvement from $3.1 million in the same period last year. The net loss for the third quarter was $1.1 million, or $0.13 per share. BioRestorative said it ended the quarter in a “very strong financial position” with $13 million in cash and short-term investments. The company had no debt as of the end of the third quarter. “We have continued to execute well across all areas of our business and are looking forward to continuing to update investors on our progress as we close out the remainder of 2024,” says Lance Alstodt, BioRestorative’s chief executive officer. “From an operating perspective, we are thrilled with our third quarter results, as we are seeing initial progress on our path to sustainable profitability, driven by cost containment activities coupled with increased resources dedicated to our commercial programs.” Commercial Programs Making Inroads BioRestorative’s commercial programs got a boost late in the quarter when it announced it obtained a provisional license from the New York State Department of Health (NYSDOH) to process, isolate, expand and preserve allogeneic (non-autologous) donor tissue, including stem cells, for medical research. Previously BioRestorative was licensed by the NYSDOH to act as a tissue bank for the processing of mesenchymal stem cells derived from autologous donors only. “It will significantly enhance our ability to develop an unrivaled clinical pipeline of off-the-shelf cell-based biologic products,” says Alstodt. Meanwhile, the company’s product, ThermoStem®, which uses adipose-derived (brown fat) stem cells to generate new brown fat tissue to target obesity and metabolic disorders, drew attention during the quarter. BioRestorative shared details of the ThermoStem platform at IFATS 2024, the annual industry conference focused on adipose therapeutics and science. BioRestorative believes cell-based therapy candidates generated from its ThermoStem program may allow for lower dosing than GLP-1 obesity drugs or provide an alternative biologic-based treatment. Studies have shown brown fat activation in addition to weight loss, can lead to positive effects on several organs, including the heart, liver and muscle. The company competes with giants like Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) in the space. During the quarter, the Israel Patent Office issued the company a Notice of Allowance for a new patent application covering several fundamental aspects of ThermoStem. It's the 14th international patent. In addition to all that, BioRestorative continued talks for a ThermoStem licensing deal with an undisclosed commercial-stage regenerative medicine company. BRTX-100 Data Encouraging In conjunction with third-quarter earnings, BioRestorative released clinical data for BRTX-100, its autologous stem cell product for chronic lower back pain. It uses a patient’s stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process. It’s targeted at the more than 25 million people in the U.S. who suffer from chronic lower back pain each year. Safety and efficacy endpoints from an ongoing phase 2 trial for the treatment of chronic lumbar disc disease (cLDD) were encouraging, BioRestorative reported. The company said no serious adverse events (SAEs) were reported in any of the 10 first patients of the prospective, randomized, double-blinded and controlled study. BioRestorative said there was also no dose limiting toxicity at 26-52 weeks. “Blinded preliminary clinical data of safety and efficacy endpoints from the ongoing phase 2 clinical trial of BRTX-100 in the treatment of cLDD are very encouraging, with patient-reported pain and function outcomes demonstrating a positive trend,” said Alstodt. “Most importantly, at 26 weeks, 70% of the patients are reporting a greater than 30% increase in function and a more than 30% decrease in pain. If data continues with this trend, we are confident that we will hit our efficacy endpoints for the phase 2 trial.” A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States. Subjects included in the trial will be randomized 2:1 to receive either BRTX-100 or a placebo. The new blinded preliminary safety and efficacy data from the ongoing phase 2 clinical trial of BRTX-100 was described in a podium presentation at the Orthopaedic Research Society (ORS) Philadelphia Spine Research Society (PSRS) 7th International Spine Research Symposium. From posting encouraging data to narrowing its losses, BioRestorative seems to be making strides on its path to profitability. With more news to come, this may be a story worth paying attention to. To learn more about BioRestorative’s stem cell therapies, click here. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 21, 2024 08:45 AM Eastern Standard Time

Image

340Bwell Presents the latest research for Optimizing STD Clinics at Global HIV and AIDS Conferences

Rev Up Marketers

340Bwell, a leader in the 340b consulting and solutions, presented their cutting edge research in two major global HIV/AIDS conferences - HIV4Prevention Conference held in Lima, Peru; and Fast Track City Conference held in Paris, France. Building upon the foundation of promoting evidence decision making within the organization and among its clients – that includes leading STD clinics of the United States – 340bwell team used regular client demographic and clinical data to uncover a diverse range of findings. In the Fast Track City Conference, the Bwell team presented a poster that highlighted the paucity of research on PrEP retention in the global south. The poster was the outcome of a systematic review being conducted by the team that examines PrEP retention and analyses the way researchers and practitioners measure it and define it. The poster revealed that the majority of the studies (>50%) were in the United States. The other two countries with a relatively large number of studies were South Africa (14.2%) and Kenya (12.5%). Bwell Managing Partner Mark Erwin also delivered a presentation on a novel telehealth model for PrEP service delivery that deployed an in-house assembled testing kits to save on cost and to expand access. In the HIV4Prevention Conference, two posters were presented. The first focussed on the science and dynamics of appointment scheduling – demonstrating that the association between client showing up and day of appointment, time slot, chosen, and if the appointment was in-clinic or telehealth was statistically significant. The second poster aimed to test the accuracy of a model that could predict if the client will show up or not using machine learning – deploying routine data. Considering that The United States' PrEP clinics have high no-show rates and not only do cancellations or no-shows result in lost opportunities to connect patients to PrEP therapy, but they also waste clinic time and resources – these findings and models can influence the way clinics can optimize their resources. Mark Erwin, the managing partner of the company said “We are excited to present evidence generated by our team at such esteemed global platforms and at the same time, learn from researchers across the world. It is truly a joyful experience to be around HIV/AIDS advocates and scientists with the common goal of reducing the impact of HIV for those who live with it or are vulnerable to it.” About 340Bwell: 340Bwell is a consulting firm specializing in optimizing 340B drug pricing programs for HIV and STD clinics. They use data-driven strategies to improve patient outcomes, clinic efficiency, and care access. Their innovative solutions have been presented at global HIV/AIDS conferences. 340Bwell is committed to advancing healthcare for underserved populations. For more information visit https://340bwell.com/ Contact Details 340bwell Harsh Agarwal - Data Scientist +1 919-903-1531 harsh@340bwell.com Company Website https://340bwell.com/

November 21, 2024 07:59 AM Eastern Standard Time

Image

LogicMark Offers Safety Technology for Free To American Veterans Nationwide

Benzinga

By Meg Flippin, Benzinga Falls are the leading cause of injury and death among aging adults in America, including our nation’s 8.1 million veterans over 65. Due to chronic conditions and physical disabilities, they are actually more susceptible to falls than their non-veteran counterparts. With more than one in five veterans living alone in America, many are in unsafe situations. Staying strong and healthy is the best way to prevent falls, but there are many other ways to decrease the risk. Making simple updates in the home, such as removing throw rugs, improving lighting, installing grab bars, using bed rails, widening hallways and doorways and adding ramps outside, can enhance safety and prevent common accidents. But even so, a fall may still occur. Unfortunately, constant physical monitoring and surveillance aren’t possible for a lot of people, and how quickly help comes could mean the difference between a non-fatal or fatal injury. That’s where LogicMark Inc. (NASDAQ: LGMK), a leading provider of personal emergency response systems (PERS), health communication devices and IoT technologies, is making a significant impact for those in these situations. Instead of relying on in-person monitoring, the company uses advanced technology to offer a comprehensive suite of products aimed at protecting users from falls both at home and on the go. Confidence And Independence In A Compact Device LogicMark’s Freedom Alert Mini is a compact 4G LTE device that allows users to call for help with just the push of a button, ensuring help is always within reach wherever there is cellular service. The Freedom Alert Mini is equipped with LogicMark’s patented fall detection technology which uses accelerometer sensors that measure the user’s speed and orientation to detect a fall. When a fall has been detected, the device sends an alert to a 24/7 monitoring center, a loved one or 911. This can be life-saving if a user falls and is unable to dial an emergency contact due to an injury, loss of consciousness, or disorientation. In addition to its fall detection capabilities, the device features GPS location services that can pinpoint the exact location of a fall and alert authorities and caregivers. It also includes geofencing capabilities, allowing caregivers to establish a virtual boundary for their loved ones. If the device user moves beyond this designated area, caregivers receive an immediate alert. Guardian Alert 911 Plus is an additional on-the-go device in LogicMark’s product line. It is designed to enhance safety both inside and outside the home and features 4G LTE technology that enables users to connect directly to 911 with a single button press. Additionally, the device includes a two-way communication feature, allowing users to speak directly with 911 operators during emergencies. This functionality provides users with the confidence to live independently, knowing help is just a call away. Veterans Can Feel Safe At Home 70% of falls occur indoors. For veterans who spend considerable time at home, LogicMark’s Freedom Alert and Guardian Alert 911 offer reliable solutions to enhance safety and peace of mind. Both wearable medical devices use the customer’s landline to connect to emergency services. The Freedom Alert allows users to quickly connect with friends, family or 911 in an emergency. With the push of a button, the device can call up to four pre-programmed contacts or dial 911 directly. Emergency responders can pinpoint the location of a LogicMark device within a 600-foot radius of the base unit. The Guardian 911 connects directly to emergency services with a single button press. Ensuring users can easily call for help or notify a caregiver even during stressful or confusing moments. Both devices feature long-lasting batteries that last at least one month. These devices give aging adults freedom and confidence, knowing help is a push of a button away. For caregivers and loved ones, the devices offer an added layer of monitoring and peace of mind when they cannot be present. Meanwhile, first responders receive crucial information that enables them to reach the scene quickly and efficiently. Globally, the fall detection systems market is forecasted to grow at a CAGR of 7.6% from now through 2030. Driving that growth is the demand for solutions to ensure the aging adult population's safety and independence with devices that can aid in home health care. LogicMark’s products check off both boxes. Aging adults over 65 make up half the nation’s veterans, and just like their non-veteran counterparts, they are at risk of falls. As the population ages, demand for devices that detect falls is projected to grow. LogicMark aims to capitalize on this growth, positioning its devices – from the Freedom Alert Mini to the Guardian Alert 911 Plus – as potential leaders in the market. Take a glance at LogicMark’s stock chart here. Featured photo by sydney Rae on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 20, 2024 08:45 AM Eastern Standard Time

Image

News Release

Consumers Primed to Spend on Cannabis, New Poll Finds

NuggMD

A majority of frequent cannabis consumers say their spending on cannabis has gone up during the past year, and a plurality say they expect it to continue to rise over the next year, according to a new consumer poll released today by NuggMD. The poll shows 61% of respondents report spending “more” or “much more” on cannabis over the past year. Forty-five percent said they expect their spending on cannabis products to continue to rise over the next year, while just 25% signaled an intention to reduce their spending. The poll was first reported by Marijuana Moment. “While our poll is a far cry from cash on hand for cannabis retailers and cultivators, it shows that demand is strong and is likely to become stronger in the near term,” said Andrew Graham, head of communications at NuggMD. “This data says that the demand side of the market is durable and highly resilient. Cannabis might be among the most recession-proof consumer products, because most cannabis use is rooted in wellness, not indulgence.” Methodology The two polls were conducted from Oct. 10 to Oct. 13 and Oct. 17 to Oct. 20 and have a margin of error of 5.9% and 4.8%, respectively. NuggMD regularly conducts polls and market research on cannabis using a sample of nearly 1.2m frequent cannabis consumers who live in state-legal markets. The company’s polling capabilities are derived from first-party data it has collected and used since launching in 2015. About NuggMD NuggMD is the nation’s leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They’ve connected over 2,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the potential benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

November 19, 2024 03:09 PM Eastern Standard Time

PathAI Announces Integrations with Leading AI-pathology Companies Deep Bio, DoMore Diagnostics, Paige, and Visiopharm, through its AISight Image Management System

PathAI

PathAI, a global leader in AI-powered digital pathology solutions and the developer of the market-leading AISight 1 Image Management System (IMS), today announced the integration of several AI products from market leading digital pathology companies, including Deep Bio, DoMore Diagnostics, Paige, and Visiopharm. Through these collaborations, PathAI will provide algorithms from these developers directly within its AISight IMS, reinforcing its commitment to offering the most versatile, reliable, and interoperable IMS on the market. Deep Bio "Integrating Deep Bio's DeepDx Prostate with PathAI's AISight platform marks an important step forward in prostate cancer diagnostics, combining AI-driven pathology insights with robust image management capabilities to support streamlined workflows," said Sun Woo Kim, CEO of Deep Bio. "This collaboration brings advanced data-driven tools to the hands of pathologists globally, enabling more efficient pathology processes and reinforcing our commitment to innovation in cancer diagnostics." — DoMore Diagnostics “DoMore Diagnostics and PathAI have a shared vision to realize the promise of digital pathology and outcome prediction to improve the lives of patients worldwide,” said Torbjørn Furuseth, Co-Founder and CEO of DoMore Diagnostics. “The AISight platform is set to spearhead innovations in the field going forward and will be a key partner as we continue our mission to personalize cancer treatment for patients worldwide with our Histotype Px digital biomarker.” — Paige "We see the partnership with PathAI as an important step forward for digital pathology; as the two leaders in this space, by offering our solutions together, pathologists can benefit from all the best things the industry can offer," said Peter Hamilton, GM of Diagnostics. — Visiopharm “We are delighted to collaborate with PathAI to bring our portfolio of fully automated, zero-click AI-driven diagnostic and translational solutions for breast and lung cancer to a broader audience. Our commitment is to expand access to precision pathology on leading platforms. Becoming a preferred partner for PathAI's AISight Image Management System is an important step towards this goal. With our platform-agnostic technology designed for seamless integration, we look forward to working closely with the PathAI team to accelerate the adoption of digital pathology worldwide, ultimately enhancing lab efficiency and improving the quality of patient care,” said Michael Grunkin, CEO Visiopharm — Utilizing the AISight IMS, partner laboratories will be able to seamlessly access a diverse portfolio of digital pathology algorithms from leading global AI companies. Through these deep integrations pathologists will benefit from rich visual support, including AI-generated overlays, and embedded quantitative results driving differentiated workflows. This integrated user experience will allow labs to realize the most value from algorithm product usage in their routine lab workflows. AISight’s growing portfolio of algorithms supports various needs, including workflow optimization, biomarker quantification, risk stratification, slide quality control, and tumor sufficiency. These integrations are powered by AISight Link, an open API that allows algorithm developers to leverage the platform’s advanced features, including AI Impressions, Fields of Interest, and comprehensive reporting tools. “These partnerships are a testament to our commitment to building a robust ecosystem of AI and digital pathology innovators,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “Through AISight Link, we ensure seamless interoperability between AISight and third-party AI algorithms, as well as integration with Laboratory Information Systems (LIS) and other essential IT infrastructure in modern pathology labs. We are excited to collaborate with labs and AI developers to collectively drive improvements in patient outcomes.” For more information about PathAI, AISight, or the expanding algorithm catalog, please contact digital.dx@pathai.com or visit pathai.com. 1 AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK About PathAI PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe. About Deep Bio Deep Bio is a pioneer in AI-powered pathology, transforming cancer diagnostics with innovative solutions that support pathologists in delivering precise and efficient care. Its flagship product, DeepDx Prostate, is a CE-IVD-marked diagnostic aid extensively vetted through studies of over 700,000 U.S. biopsy specimens. Offering tools for cancer detection, Gleason scoring, and gland-level tumor analysis, DeepDx Prostate enhances diagnostic accuracy while streamlining pathology workflows. Deep Bio's commitment to advancing digital pathology is driven by collaboration and a dedication to improving patient outcomes. About DoMore Diagnostics DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists' existing workflow. The lead product Histotype Px ® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor. About Paige Paige's AI applications are developed using extensive and diverse datasets and leverage advanced AI technologies. Thoughtfully designed, rigorously tested, and trusted by pathologists worldwide for their performance. By automating traditionally burdensome and tedious manual tasks, Paige's AI applications alleviate time and resource pressures for pathologists. All of Paige's AI suites including Prostate, Breast, Colon, Pan-Cancer, and the new biomarker screening application, OmniScreen™ will be made available within PathAI's digital pathology solution, AISight. About Visiopharm Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company's headquarters are located in Denmark's Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 19, 2024 09:19 AM Eastern Standard Time

1 2 3 4 5 ... 303